Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026. The transaction was funded through the issuance of 28.9 million shares of Class A common stock and incremental borrowings totaling $350.0 million under Amneal's existing term loan and revolving credit facility. This filing serves as an amendment to include Kashiv's historical financial statements, pro forma combined financial information, and related auditor consents required by SEC regulations. The company operates in the pharmaceutical industry.
